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Background: The prognosis of patients with resected non–small cell lung cancer
without carcinomatous pleuritis whose intrapleural cancer cells were detected by
means of a cytologic examination of pleural lavage fluid obtained immediately after
a thoracotomy has been reported to be poor.
Methods: The Japan Clinical Oncology Group conducted a phase III trial for a
3-year period starting from October 1994 to determine whether intraoperative
intrapleural hypotonic cisplatin treatment could effectively control pleural disease
and thereby prolong the survival of these patients. The patients were randomized to
receive either intraoperative intrapleural hypotonic cisplatin treatment or no treat-
ment before closure of the open thorax. The intraoperative intrapleural hypotonic
cisplatin treatment consisted of exposing the entire thorax to cisplatin (50 g/mL)
in distilled water for 15 minutes.
Results: Because of the slow registration pace, the study was prematurely terminated
in January 1998. During the 41-month period from the start of the registration, 49
patients were entered into the study, and all were eligible. Twenty-five and 24
patients were randomly assigned to the treatment and control groups, respectively.
No statistically significant difference in the overall survival and disease-free sur-
vival between the 2 groups was observed. However, the appearance of carcinoma-
tous pleuritis was suppressed by the hypotonic cisplatin treatment (42% of the
control group vs 8% of the treatment group, P  .008).
Conclusions: Although the randomized trial was prematurely terminated, the intra-
operative intrapleural hypotonic cisplatin treatment was found to effectively sup-
press the appearance of carcinomatous pleuritis in resected patients who demon-
strated a positive pleural lavage cytology finding.
The presence of cancer cells in the intrapleural space has been re-ported in a certain percentage of patients with non–small cell lungcancer without carcinomatous pleuritis (malignant pleural effusion,disseminated pleural tumors, or both) who underwent an operationon the basis of the findings of a cytologic examination of intrapleurallavage fluid collected immediately after a thoracotomy.1-6 On the
whole, the prognosis of such patients has been reported to be poor, and the pattern
of recurrence has yet to be intensively analyzed. However, considering the site of
such cancer cells, the occurrence of carcinomatous pleuritis as a recurrence can be
predicted in such patients.
We developed an intraoperative intrapleural treatment regimen in which distilled
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water was combined with cisplatin for patients with carci-
nomatous pleuritis found at thoracotomy. According to our
experimental data, the hypotonic cisplatin solution showed
a significantly stronger antitumor activity than either the
isotonic cisplatin solution or distilled water alone.7 In a
single institutional clinical trial, this treatment modality,
which is called hypotonic cisplatin treatment, seemed to
effectively control carcinomatous pleuritis without any ad-
verse events.8 As a result, the Surgical Lung Cancer Study
Group of the Japan Clinical Oncology Group (JCOG)
started a randomized phase III trial to determine whether
intraoperative intrapleural hypotonic cisplatin treatment can
effectively control pleural disease and thus prolong sur-
vival. However, this trial was prematurely terminated be-
cause of a poor registration pace. Although the analysis of
results from such a failed trial should be limited, the recur-
rent patterns, including carcinomatous pleuritis, that were
prospectively observed are considered worthy of analysis.
We therefore focused on that aspect in this study.
Methods
Patients
The patients who were eligible for this study consisted of those
with non–small cell lung cancer who had cancer cells detected by
means of a cytologic examination of the intrapleural lavage fluid
collected immediately after opening the thorax. All such patients
had to undergo a macroscopically complete resection of the dis-
ease, which ranged from surgical stage I to IIIA. Neither any
malignant pleural effusion nor disseminated pleural tumors could
be found at thoracotomy. Before operation, all eligible patients
were required to be 75 years of age or younger, have an estimated
postoperative FEV1.0 of greater than 600 mL/m2, have a leukocyte
count of 3000/L or greater, have a hemoglobin level of 10 g/dL
or greater, have a platelet count of 100,000/L or greater, have a
serum bilirubin level of 1.5 mg/dL or less, have serum glutamic
oxaloacetic transaminase-glutamic pyruvic transaminase levels of
no more than twice the upper limit of normal, have a serum
creatinine level of 1.5 mg/dL or less, and have a blood urea
nitrogen level of 25 mg/dL or less. Patients who either underwent
a combined resection of the chest wall or pericardium or those with
a broad range of pleural adhesion were also excluded from the
study.
Design and Procedure
This trial was initiated by the Lung Cancer Surgical Study Group
of the JCOG in October 1994, and the trial was prematurely
terminated in January 1998 because of a slow registration pace.
Registration was done by fax at the data center of the JCOG during
the operations. All patients underwent randomization, and the
operator was informed of the randomized result before the end of
the operation. The patients were stratified according to surgical
stage (I vs II  III A-N0, 1 vs IIIA-N2).9 The primary endpoint of
the study was the incidence of the appearance of clinically detected
carcinomatous pleuritis and the overall survival, and the secondary
end point was the disease-free survival and safety assessment. The
institutional review board or the ethics committee at each site
reviewed and approved the protocol. Written informed consent
was obtained from all patients.
Immediately after opening the thorax, the pleural cavity was
gently washed with 50 mL of saline. To obtain only cancer cells
present in the intrapleural space, we avoided touching any of the
pleural surfaces on the primary tumor. Next, 20 mL of the lavaged
fluid was collected and put into a tube containing ethylenediamine
tetraacetic acid. The obtained sediment was stained with Giemsa
and the Papanicolaou method and with Alcian blue to determine
the presence or absence of cancer cells.
The patients assigned to the control group received no treat-
ment after the tumor was resected, and the open thorax was closed
after washing the thorax with saline. Patients randomized to the
treatment group received the intraoperative intrapleural hypotonic
cisplatin treatment before closure of the open thorax.7,8 After
completing the intrathoracic surgical procedures, the thoracic cav-
ity was washed out with saline to remove any blood, and then it
was washed out an additional 2 more times with distilled water to
efficiently remove any remaining blood cells by means of hemo-
lysis. Thereafter, the entire thoracic cavity was exposed for 15
minutes to cisplatin in distilled water that had been prewarmed to
38°C to 40°C. The cisplatin concentration used was 50 g/mL.
After removing the solution by means of suction and washing out
the thoracic cavity with saline, 2 chest tubes for patients with a
lobectomy and one chest tube for those with a pneumonectomy
were inserted, and then the thoracic cavity was closed. Perioper-
ative hydration was not specifically performed.
The performance of postoperative chemotherapy was not al-
lowed until recurrence was identified. Radiotherapy after the op-
eration was performed at the physician’s discretion.
All patients were required to undergo bronchoscopy, bone
scintigraphy, and a computed tomography (CT) scan of the thorax,
including the level of the adrenal glands, before the operation. A
follow-up examination was performed every 3 months for 5 years.
The examination included a physical examination, measurement of
serum tumor markers, and chest radiography every 3 months and
a CT scan of the thorax, including the level of the adrenal glands,
as well as bone scintigraphy, every 6 months for 5 years. The site
of a first recurrence, including carcinomatous pleuritis, was noted
obligatorily. Recurrence caused by carcinomatous pleuritis was
defined as follows: (1) the appearance of pleural effusion in which
the presence of cancer cells was proven by a cytologic examina-
tion; (2) the enlargement of an irregular-shaped pleural thickness
shadow or pleural mass shadow confirmed by successive CT
scans; and (3) cancer in either the pleural thickness or pleural mass
detected by means of CT scans and proved by means of a patho-
logic examination.
Statistical Analysis
This trial was designed to test the hypothesis that the 3-year
survival rate would be 30% in the control group and 50% in the
treatment group. The estimated sample size with an  error of .05
and a  error of .2 was 100 patients in each group within a 3-year
period.
In the present study the overall and disease-free survivals were
defined as the time from operation until death from any cause and
the time from operation until either death from any cause or a first
recurrence. The survival curves were made by using the Kaplan-
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Meier method, and a statistical evaluation of the curves was done
by means of a log-rank test. Differences between the proportions
were evaluated with the 2 test.
Results
Although a total of 200 patients had been scheduled to be
enrolled in this phase III trial during the 3-year period from
October 1994, the pace of the patient registration was so
slow that the trial was terminated prematurely as of January
1998. During the 41-month period from the start of the
registration, only 49 eligible patients were enrolled in the
study and randomly assigned to either the hypotonic cisplat-
in treatment group (25 patients) or the control group (24
patients). All patients underwent a lobectomy. Although
performance of postoperative chemotherapy was not al-
lowed until recurrence was observed, 1 patient in the control
group did receive chemotherapy. Two patients in the treat-
ment group underwent postoperative radiotherapy. The
other patient characteristics are shown in Table 1. The ratio
of adenocarcinoma in the treatment group was higher than
that in the control group (P  .0502), but the proportion of
other items was well balanced between the 2 groups.
In the treatment group the dose (mean SD) of cisplatin
and the volume of distilled water actually used were 78.4 
24.9 mg (range, 50-100 mg) and 1488  262 mL (range,
500-2000 mL), respectively. The actual exposure time was
13.2  3.4 minutes (range, 10-20 minutes).
The median time from registration to the last follow-up
in the 26 surviving patients was 49 months (range, 29-72
months). As shown in Figures 1 and 2, no statistical differ-
ence in the overall survival and the disease-free survival
between the treatment and control groups was observed.
However, the appearance of the carcinomatous pleuritis was
suppressed by the hypotonic cisplatin treatment (Table 2).
Carcinomatous pleuritis was observed in 10 (63%) of 16
patients with recurrence in the control group or in 10 (42%)
of all 24 patients in the control group, whereas only 2 (17%)
of 12 patients with recurrence in the treatment group (P 
.024) or 2 (8%) of all 25 patients in the treatment group
(P  .008) had carcinomatous pleuritis. The length of time
until the appearance of carcinomatous pleuritis from the
operation was 7 and 48 months in 2 patients in the treatment
group, respectively, and the same median time in 10 patients
in the control group was 18 months (range, 6-38 months), as
shown in Figure 2. Among a total of 12 patients with
carcinomatous pleuritis, malignant pleural effusion was ob-
served in 8 patients, pleural disseminated tumors in 3 pa-
tients, and both in 1 patient. Systemic recurrence was ob-
served in 8 patients in the treatment group and in 7 patients
in the control group (Table 2).
Concerning postoperative complications, pneumonia was
noted in 2 patients in the treatment group and in 1 patient in
the control group. Arrhythmia and prolonged alveolar air
leakage was observed in 1 patient each in the treatment
group. However, neither any operative deaths nor treatment-
related deaths were observed.
Discussion
When the protocol was approved by the JCOG, approxi-
mately 100 patients undergoing resection with non–small
cell lung cancer and a positive pleural lavage cytology
finding per year were predicted in the Lung Cancer Surgical
Group of the JCOG on the basis of a questionnaire survey
performed by the group. The main reasons for the failure of
this phase III trial are considered to be as follows. Intraop-
erative intrapleural hypotonic cisplatin treatment was not
TABLE 1. Patient characteristics
Treatment group
(n  25)
Control group
(n  24) P value
Age (y) 60.9 9.1 58.5 8.0 .334
Male/female ratio 10/15 8/16 .628
Histology
Adenocarcinoma 25 20 (83%) .050
Others 0 4
Pathologic T factor
T1 6 (24%) 7 (29%) .981
T2 17 (68%) 15 (63%)
T3 1 1
T4 1 1
Pathologic N factor
N0 14 (56%) 14 (58%) .815
N1 3 4
N2 8 (32%) 6 (25%)
Pathologic stage
I 12 (48%) 13 (54%) .708
II 3 4
III 10 (40%) 7 (29%)
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well known by doctors in the trial group. In addition, it was
difficult to obtain informed consent from patients to join the
intraoperative randomized trial.
Although the number of patients analyzed in the present
study was small because of the prematurely terminated trial,
the number of patients who underwent intraoperative pleu-
ral lavage cytology for this trial was estimated to be several
hundred. The frequency of a positive cytology finding in
patients without carcinomatous pleuritis who underwent a
cytologic examination of pleural lavage fluid collected im-
mediately after a thoracotomy has been reported to be 9%
(14/158 patients),2 9% (42/467 patients),3 and 14% (11/78
patients).4 Buhr and colleagues5 reported an extraordinarily
high frequency of 39% (132/342 patients). We have recently
reported the results of 1890 patients who underwent pleural
lavage cytology immediately after a thoracotomy in JCOG6;
142 (8%) of them were found to have intrapleural cancer
cells detected by means of a cytologic examination. On the
basis of the above findings, and excluding the exceptional
findings of Buhr and colleagues, a positive rate of approx-
imately 10% is considered to be most likely. Because the
total number of patients analyzed in the present study was
49, about 500 patients were thus considered to have under-
gone a cytologic examination for the trial.
Although the long-term survival rate was not determined
in the present study, the 3-year survival rate was relatively
reliable because the median time of follow-up in 26 surviv-
ing patients was 49 months. As shown in Figure 1, the
3-year survival rate was 68% in the treatment group and
67% in the control group. These survival rates appeared to
be higher than those of other series. According to the results
of the 3 reports, the 3-year survival rates ranged from 23%
to 44%.2,3,5,6 In a previous study we observed that the
prognosis of patients with pathologic stage I disease was
significantly better than that of other patients, even in pa-
tients with intrapleural cancer cells detected by means of a
cytologic examination.6 In this study the proportion of pa-
tients with pathologic stage I disease was 48% in the treat-
ment group and 54% in the control group, whereas the same
proportions in the other series mentioned above ranged from
17% to 43%. Therefore the difference in the proportion of
stage I disease might influence the differences in the 3-year
survivals to some extent.
Because cancer cells are present in the intrapleural space
in those patients, they are expected to have carcinomatous
pleuritis postoperatively. However, the recurrent patterns of
such patients are still not well known. In retrospective
studies the appearance of carcinomatous pleuritis after an
operation has been reported to be observed in 2 (9%) of 23
patients2 and in 11 (26%) of 42 patients.3 In this prospective
study 10 (42%) of 24 patients in the control group were
found to have carcinomatous pleuritis. This also means that
recurrence caused by carcinomatous pleuritis was observed
Figure 1. Overall survival curves of patients in the control and
treatment groups.
Figure 2. Disease-free survival curves of the patients in the
control and treatment groups. Filled and open circles represent
patients with carcinomatous pleuritis in the treatment and control
groups, respectively.
TABLE 2. Site of first recurrence
Treatment
group
(n  25)
Control
group
(n  24)
Local recurrence only 4 9
Carcinomatous pleuritis 2 9
Others 2 0
Systemic recurrence only 8 6
Bone 3 2
Brain 1 1
Lung 4 2
Lung  liver 0 1
Local  systemic 0 1
Carcinomatous pleuritis  bone 0 1
Total 12 (48%) 16 (67%)
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in 63% of patients with recurrence in the control group. On
the other hand, the appearance of carcinomatous pleuritis
was significantly suppressed by the intraoperative intrapleu-
ral hypotonic cisplatin treatment. Only 2 (8%) of 25 patients
in the treatment group had carcinomatous pleuritis, and this
was equal to the 17% of the patients with recurrence in this
group. On the basis of these findings, we are now planning
to perform a prospective registry by using this intraopera-
tive intrapleural hypotonic cisplatin treatment on patients
with a positive pleural lavage cytology finding to obtain
further information on survival, the recurrence patterns and
adverse events from numerous treated patients, and also to
familiarize doctors in this trial group with the hypotonic
cisplatin treatment modality.
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